The U.S. Department of Health and Human Services recently announced it will temporarily allow compounding pharmacies to make six peptides available by prescription.
In a Semafor article, life sciences regulatory & compliance partner Josh Oyster noted that HHS leadership shifts or potential future safety issues could lead to a “rethinking” of peptide policy under HHS’ limited enforcement discretion.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.